Renal cell carcinoma - The Lancet

The multispeciality approach to the management of localised kidney cancer - The Lancet

Kidney Cancer Weill Cornell Medicine: Department of Urology - New York

Kaplan–Meier estimates of progression-free survival. Reprinted from The

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study - The Lancet Digital Health

Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology - The Lancet Oncology

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study - The Lancet Oncology

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial - The Lancet

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial - The Lancet

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study - The Lancet Oncology

Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma - The Lancet Oncology

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study - The Lancet Oncology

Is tailored systemic therapy in renal cell carcinoma realistic? - The Lancet Oncology

Targeting VEGF receptors in kidney cancer - The Lancet Oncology

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study - The Lancet Oncology